Similarly, DFX treatment led to a dose-dependent increase in the expression of TfR1 and the downregulation of FPN and FTH1 in MG-63, MNNG/HOS and K7M2 osteosarcoma cells. Here, SLC40A1 is linked to osteosarcoma.